Revolution Medicines draws USD 250 million Royalty Pharma Tranche A term loan after FDA approval of RASONQUE
Revolution Medicines drew USD 250 million under Royalty Pharma’s senior secured term loan facility tied to FDA approval of RASONQUE (daraxonrasib). Funding occurred on Oct. 8, 2026 under Tranche A of a USD 750 million facility arranged with Wilmington Trust as administrative agent. Draw carried a USD 5 million fee; int